I bet clinical trials are progressing well,
Now that the radioactive element IS available again...bloody Government delay last year!
Yes, clinical trial progress is reportedly OUTSTANDING.
This company will monetize its efforts sooner than most think here.
REJECT DISINFORMATION AND DO YOUR OWN RESEARCH.
READ! TALK TO CLRB IR ...live long and prosper.
For example:
Cellectar Biosciences Reports Median Survival of 22 Months in Ongoing Phase 1 Trial Evaluating CLR 131 for Relapsed/Refractory Multiple Myeloma
BY MT Newswires
— 4:06 PM ET 01/07/2019
04:06 PM EST, 01/07/2019 (MT Newswires) -- Cellectar Biosciences ( CLRB
Loading...
Loading...
) announced median overall survival (mOS) in cohorts 1 to 4 of the company's ongoing phase 1 clinical trial evaluating CLR 131 for the treatment of relapsed/refractory (R/R) multiple myeloma (MM).
The results showed mOS of 22 months among 15 patients, all of whom were heavily pretreated, averaging five prior lines of systemic therapy. Each patient in cohorts 1 to 4 of the dose-escalation study received a single 30-minute infusion of CLR 131.
"The median overall survival of 22 months in this heavily pretreated patient population is very encouraging. These are patients with limited therapeutic options and, unfortunately, face poor prognoses," said James Caruso, president and chief executive officer of Cellectar Biosciences ( CLRB
Loading...
Loading...
).
"The convenience afforded by CLR 131 delivered in only one or two doses as currently administered in our ongoing hematology studies makes it a far less intrusive regimen than other treatments that must be administered at regular dosing intervals. We believe extending mOS with a more patient-friendly dosing regimen provides both a distinctive product profile and the potential to provide beneficial patient outcomes even in later lines of therapy," Caruso added.
Price: 1.8600, Change: +0.1400, Percent Change: +8.14
